Analysts evaluate whether Aurinia Pharmaceuticals' recent patent settlement for its kidney disease drug LUPKYNIS with Teva could drive significant stock gains for investors.

Teva Pharmaceuticals has been granted priority review by the FDA for its new therapy aimed at treating Tourette syndrome, potentially accelerating its path to market.

The CEO of Teva Pharmaceuticals provided insights into the company's drug pipeline and discussed the potential for a direct listing on the New York Stock Exchange.

Wall Street analysts are optimistic about Teva Pharmaceuticals, predicting its stock could soar over 60%. The article explains the reasons behind this positive outlook from financial experts.

Teva Pharmaceuticals has submitted a New Drug Application (NDA) for ecopipam, a medication intended for the treatment of Tourette's syndrome in pediatric patients.

Teva Pharmaceuticals (TEVA) experienced a 12% surge in its stock price after reporting new record profits.

A financial analyst suggests a particular dividend stock as a superior value investment compared to Teva Pharmaceuticals.

Struggling biotechnology company BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection and formally entered into an asset sale agreement to transfer its remaining intellectual property and product portfolio to Israeli drugmaker Teva Pharmaceuticals.

Teva Pharmaceuticals, a leading global manufacturer, reportedly does not want to emphasize its identity as an Israeli company in a lawsuit in the United States.

Teva Pharmaceuticals CEO Richard Francis spoke about the company's positive second-quarter earnings, the upcoming impact of changes to Medicare rules on patients, and the company's planned direct listing on the New York Stock Exchange.

Teva Pharmaceuticals' stock is on track to break a seven-session losing streak, indicating a potential turnaround in its market performance.

UroGen Pharma has reached a settlement with Teva Pharmaceuticals regarding a patent dispute concerning its drug Jelmyto.

Teva Pharmaceuticals received an award for advancing gender equality, with women now making up 43% of its senior management in Israel. The recognition highlights the company's efforts in representation, equal pay, and inclusive workplace policies.

Corcept Therapeutics' stock declined after an appeals court ruled in favor of Teva Pharmaceuticals in a patent dispute concerning Corcept's drug Korlym.

Teva has disclosed plans to acquire a new neuroscience asset as part of its strategic pivot toward growth and disciplined business development.

Teva Pharmaceuticals is seeking to prevent its ties to Israel from being presented to a jury, citing the ongoing Gaza war. The company argues that this information could prejudice the jury.

An article discusses the successful turnaround of Teva Pharmaceuticals and identifies a key factor that could lead to a significant increase in its stock value.

New data released for the drug Austedo is providing Teva Pharmaceuticals with renewed reasons for optimism regarding its prospects.

Teva Pharmaceutical Industries announced its first-quarter earnings, showing a surge in AUSTEDO sales. The company also revealed plans for a $700 million buyout of Emalex.

Financial analysts have identified three key catalysts that could potentially drive Teva Pharmaceuticals stock to $40 and beyond. This analysis provides insights into the company's future market performance.